Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class A 002399

SZSE · China · Health Technology

CNY 9.85+0.24 (+2.50%)

Market closed· Sep 30, 2026, 7:04 AM UTC· CNY · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class A 002399

SZSE · China · Health Technology

CNY 9.85+0.24 (+2.50%)

Market closed· Sep 30, 2026, 7:04 AM UTC· CNY · Data may be delayed

Company news

Yahoo FinanceMay 11, 2026

Resverlogix Announces One-Year Extension of Debenture

Calgary, Alberta--(Newsfile Corp. - May 11, 2026) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") announced today a one-year extension of the Company's US$6.0 million secured debenture with Shenzhen Hepalink Pharmaceutical Group Co., Ltd. ("Hepalink") (and payment of accrued interest thereon), extending the maturity date to May 13, 2027. In connection with the extension, the interest rate has been amended from 18% to 20% per annum, commencing on May 14, 2026."We appreciate...

Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.

Prices may be delayed and are for informational purposes only - not investment advice.